Skip to main content

Advertisement

SpringerLink
Log in

Acute kidney injury in cancer patients

  • Review article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Objective

We want to know the causes of AKI in oncology patients, including disease-related complications and the nephrotoxicity of chemotherapy drugs, in order to provide more useful clinical information.

Methods

In this review, an electronic search of the English language literature was performed in the database PubMed, with the results enriched by manual searches and citation mining, factors investigated in the selected articles included acute kidney injury, oncology, chemotherapy, anticancer drug, antitumor drug.

Results

According to the searched articles, we summarized the causes (including pre-renal, intrinsic renal, and post-renal lesion) of AKI in cancer patients and the corresponding management measures. Among the pre-renal factors we mainly described hypercalcemia, hematopoietic cell transplantation, post-renal factors we mainly described hemorrhagic cystitis, and intrinsic renal factors we mainly described thrombotic microangiopathy, chemotherapeutics, tumor lysis syndrome, cast nephropathy, in which the emphasis was on chemotherapy drug associated AKI and its treatment.

Conclusions

AKI is not uncommon in cancer patients, and has diverse causes and negative outcomes. Both nephrologists and oncologists need to be aware of the unique reasons of AKI in this population and its optimal management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cheng Y, Nie S, Li L, Li Y, Liu D, Xiong M, et al. Epidemiology and outcomes of acute kidney injury in hospitalized cancer patients in China. Int J Cancer. 2019;144(11):2644–50. https://doi.org/10.1002/ijc.31993.

    Article  CAS  PubMed  Google Scholar 

  2. Fidler MM, Bray F, Soerjomataram I. The global cancer burden and human development: a review. Scand J Public Health. 2018;46(1):27–36. https://doi.org/10.1177/1403494817715400.

    Article  PubMed  Google Scholar 

  3. Mattiuzzi C, Lippi G. Current cancer epidemiology. J Epidemiol Glob Health. 2019;9(4):217–22. https://doi.org/10.2991/jegh.k.191008.001.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Salahudeen AK, Doshi SM, Pawar T, Nowshad G, Lahoti A, Shah P. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol. 2013;8(3):347–54. https://doi.org/10.2215/cjn.03530412.

    Article  PubMed  Google Scholar 

  5. Lam AQ, Humphreys BD. Onco-nephrology: AKI in the cancer patient. Clin J Am Soc Nephrol. 2012;7(10):1692–700. https://doi.org/10.2215/cjn.03140312.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Cosmai L, Porta C, Gallieni M, Perazella MA. Onco-nephrology: a decalogue. Nephrol Dial Transplant. 2016;31(4):515–9. https://doi.org/10.1093/ndt/gfv320.

    Article  PubMed  Google Scholar 

  7. Poston JT, Koyner JL. Sepsis associated acute kidney injury. BMJ (Clinical research ed). 2019;364: k4891. https://doi.org/10.1136/bmj.k4891.

    Article  Google Scholar 

  8. Canet E, Zafrani L, Lambert J, Thieblemont C, Galicier L, Schnell D, et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One. 2013;8(2):e55870. https://doi.org/10.1371/journal.pone.0055870.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Rosner MH, Dalkin AC. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol. 2012;7(10):1722–9. https://doi.org/10.2215/cjn.02470312.

    Article  CAS  PubMed  Google Scholar 

  10. Toka HR, Al-Romaih K, Koshy JM, DiBartolo S 3rd, Kos CH, Quinn SJ, et al. Deficiency of the calcium-sensing receptor in the kidney causes parathyroid hormone-independent hypocalciuria. J Am Soc Nephrol. 2012;23(11):1879–90. https://doi.org/10.1681/asn.2012030323.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Rosner MH, Perazella MA. Acute kidney injury in the patient with cancer. Kidney Res Clin Pract. 2019;38(3):295–308. https://doi.org/10.23876/j.krcp.19.042.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Shingai N, Morito T, Najima Y, Kobayashi T, Doki N, Kakihana K, et al. Early-onset acute kidney injury is a poor prognostic sign for allogeneic SCT recipients. Bone Marrow Transplant. 2015;50(12):1557–62. https://doi.org/10.1038/bmt.2015.188.

    Article  CAS  PubMed  Google Scholar 

  13. Kagoya Y, Kataoka K, Nannya Y, Kurokawa M. Pretransplant predictors and posttransplant sequels of acute kidney injury after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(3):394–400. https://doi.org/10.1016/j.bbmt.2010.07.010.

    Article  PubMed  Google Scholar 

  14. Hosing C, Nash R, McSweeney P, Mineishi S, Seibold J, Griffith LM, et al. Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States. Biol Blood Marrow Transplant. 2011;17(5):674–81. https://doi.org/10.1016/j.bbmt.2010.08.003.

    Article  PubMed  Google Scholar 

  15. Labrador J, López-Corral L, López-Godino O, Vázquez L, Cabrero-Calvo M, Pérez-López R, et al. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. Bone Marrow Transplant. 2014;49(5):684–90. https://doi.org/10.1038/bmt.2014.17.

    Article  CAS  PubMed  Google Scholar 

  16. Hingorani S. Renal complications of hematopoietic-cell transplantation. N Engl J Med. 2016;374(23):2256–67. https://doi.org/10.1056/NEJMra1404711.

    Article  PubMed  Google Scholar 

  17. Satwani P, Bavishi S, Jin Z, Jacobson JS, Baker C, Duffy D, et al. Risk factors associated with kidney injury and the impact of kidney injury on overall survival in pediatric recipients following allogeneic stem cell transplant. Biol Blood and Marrow Transplant. 2011;17(10):1472–80. https://doi.org/10.1016/j.bbmt.2011.02.006.

    Article  Google Scholar 

  18. Gaziev J, Paba P, Miano R, Germani S, Sodani P, Bove P, et al. Late-onset hemorrhagic cystitis in children after hematopoietic stem cell transplantation for thalassemia and sickle cell anemia: a prospective evaluation of polyoma (BK) virus infection and treatment with cidofovir. Biol Blood Marrow Transplant. 2010;16(5):662–71. https://doi.org/10.1016/j.bbmt.2009.12.009.

    Article  CAS  PubMed  Google Scholar 

  19. Parikh CR, Yarlagadda SG, Storer B, Sorror M, Storb R, Sandmaier B. Impact of acute kidney injury on long-term mortality after nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14(3):309–15. https://doi.org/10.1016/j.bbmt.2007.12.492.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Lopes JA, Jorge S, Neves M. Acute kidney injury in HCT: an update. Bone Marrow Transplant. 2016;51(6):755–62. https://doi.org/10.1038/bmt.2015.357.

    Article  CAS  PubMed  Google Scholar 

  21. Yang WC, Chen YT, Chang WW, Chang CH, Fan PC, Lee SY, et al. Outcome predictors of allogeneic hematopoietic stem cell transplant. Am J Med Sci. 2013;345(1):33–8. https://doi.org/10.1097/MAJ.0b013e31824c6f29.

    Article  PubMed  Google Scholar 

  22. Mori J, Ohashi K, Yamaguchi T, Ando M, Hirashima Y, Kobayashi T, et al. Risk assessment for acute kidney injury after allogeneic hematopoietic stem cell transplantation based on Acute Kidney Injury Network criteria. Intern Med (Tokyo, Japan). 2012;51(16):2105–10. https://doi.org/10.2169/internalmedicine.51.7418.

    Article  Google Scholar 

  23. Petri CR, O’Donnell PH, Cao H, Artz AS, Stock W, Wickrema A, et al. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma. 2014;55(12):2866–73. https://doi.org/10.3109/10428194.2014.897701.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney Int. 2017;92(1):37–46. https://doi.org/10.1016/j.kint.2016.11.029.

    Article  PubMed  Google Scholar 

  25. Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157–68. https://doi.org/10.1016/j.bbmt.2009.08.024.

    Article  PubMed  Google Scholar 

  26. Kersting S, Koomans HA, Hené RJ, Verdonck LF. Acute renal failure after allogeneic myeloablative stem cell transplantation: retrospective analysis of incidence, risk factors and survival. Bone Marrow Transplant. 2007;39(6):359–65. https://doi.org/10.1038/sj.bmt.1705599.

    Article  CAS  PubMed  Google Scholar 

  27. Spitzer TR. Engraftment syndrome: double-edged sword of hematopoietic cell transplants. Bone Marrow Transplant. 2015;50(4):469–75. https://doi.org/10.1038/bmt.2014.296.

    Article  CAS  PubMed  Google Scholar 

  28. Wanchoo R, Stotter BR, Bayer RL, Jhaveri KD. Acute kidney injury in hematopoietic stem cell transplantation. Curr Opin Crit Care. 2019;25(6):531–8. https://doi.org/10.1097/mcc.0000000000000657.

    Article  PubMed  Google Scholar 

  29. Carreras E, Fernández-Avilés F, Silva L, Guerrero M, Fernández de Larrea C, Martínez C, et al. Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center. Bone Marrow Transplant. 2010;45(9):1417–22. https://doi.org/10.1038/bmt.2009.363.

    Article  CAS  PubMed  Google Scholar 

  30. Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci. 2008;121(Pt 13):2115–22. https://doi.org/10.1242/jcs.017897.

    Article  CAS  PubMed  Google Scholar 

  31. Casadei Gardini A, Aquilina M, Oboldi D, Lucchesi A, Carloni S, Tenti E, et al. Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease. BMC Cancer. 2013;13:542. https://doi.org/10.1186/1471-2407-13-542.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481–508. https://doi.org/10.2215/cjn.04800908.

    Article  CAS  PubMed  Google Scholar 

  33. Coomes EA, Wolfe Jacques A, Michelis FV, Kim DDH, Thyagu S, Viswabandya A, et al. Efficacy of cidofovir in treatment of BK virus-induced hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2018;24(9):1901–5. https://doi.org/10.1016/j.bbmt.2018.04.009.

    Article  CAS  PubMed  Google Scholar 

  34. Höller K, Fabeni L, Herling M, Holtick U, Scheid C, Knops E, et al. Dynamics of BKPyV reactivation and risk of hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2017;99(2):133–40. https://doi.org/10.1111/ejh.12895.

    Article  CAS  PubMed  Google Scholar 

  35. Beck LH Jr. Membranous nephropathy and malignancy. Semin Nephrol. 2010;30(6):635–44. https://doi.org/10.1016/j.semnephrol.2010.09.011.

    Article  CAS  PubMed  Google Scholar 

  36. Wanchoo R, Bernabe Ramirez C, Barrientos J, Jhaveri KD. Renal involvement in chronic lymphocytic leukemia. Clin Kidney J. 2018;11(5):670–80. https://doi.org/10.1093/ckj/sfy026.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Jhaveri KD, Shah HH, Calderon K, Campenot ES, Radhakrishnan J. Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int. 2013;84(1):34–44. https://doi.org/10.1038/ki.2012.484.

    Article  CAS  PubMed  Google Scholar 

  38. Campbell GA, Hu D, Okusa MD. Acute kidney injury in the cancer patient. Adv Chronic Kidney Dis. 2014;21(1):64–71. https://doi.org/10.1053/j.ackd.2013.08.002.

    Article  PubMed  Google Scholar 

  39. Rosner MH, Perazella MA. Acute kidney injury in patients with cancer. N Engl J Med. 2017;376(18):1770–81. https://doi.org/10.1056/NEJMra1613984.

    Article  CAS  PubMed  Google Scholar 

  40. Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis. 2015;66(5):857–68. https://doi.org/10.1053/j.ajkd.2015.02.340.

    Article  CAS  PubMed  Google Scholar 

  41. Robier C, Neubauer M, Beham-Schmid C, Sill H. Thrombotic microangiopathy and disseminated intravascular coagulation associated with carcinocythemia in a patient with breast cancer. J Clin Oncol. 2011;29(34):e825–6. https://doi.org/10.1200/jco.2011.36.7433.

    Article  PubMed  Google Scholar 

  42. Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood. 2011;118(6):1452–62. https://doi.org/10.1182/blood-2011-02-321315.

    Article  CAS  PubMed  Google Scholar 

  43. Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, et al. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2011;46(5):682–9. https://doi.org/10.1038/bmt.2010.182.

    Article  CAS  PubMed  Google Scholar 

  44. Derungs A. Drug-induced acute kidney injury. Ther Umsch. 2015;72(11–12):717–27. https://doi.org/10.1024/0040-5930/a000742.

    Article  PubMed  Google Scholar 

  45. El-Ghazal R, Podoltsev N, Marks P, Chu E, Saif MW. Mitomycin–C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer. 2011;10(2):142–5. https://doi.org/10.1016/j.clcc.2011.03.012.

    Article  CAS  PubMed  Google Scholar 

  46. Garcia G, Atallah JP. Antineoplastic agents and thrombotic microangiopathy. J Oncol Pharm Pract. 2017;23(2):135–42. https://doi.org/10.1177/1078155216628324.

    Article  CAS  PubMed  Google Scholar 

  47. Glezerman I, Kris MG, Miller V, Seshan S, Flombaum CD. Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol. 2009;71(2):130–9. https://doi.org/10.5414/cnp71130.

    Article  CAS  PubMed  Google Scholar 

  48. Markowitz GS, Bomback AS, Perazella MA. Drug-induced glomerular disease: direct cellular injury. Clin J Am Soc Nephrol. 2015;10(7):1291–9. https://doi.org/10.2215/cjn.00860115.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Izzedine H, Escudier B, Lhomme C, Pautier P, Rouvier P, Gueutin V, et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine. 2014;93(24):333–9. https://doi.org/10.1097/md.0000000000000207.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res. 2011;17(18):5858–66. https://doi.org/10.1158/1078-0432.Ccr-11-0804.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. den Deurwaarder ES, Desar IM, Steenbergen EJ, Mulders PF, Wetzels JF, van Herpen CM. Kidney injury during VEGF inhibitor therapy. Neth J Med. 2012;70(6):267–71.

    Google Scholar 

  52. Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med. 2009;122(4):322–8. https://doi.org/10.1016/j.amjmed.2008.11.025.

    Article  CAS  PubMed  Google Scholar 

  53. Bollée G, Patey N, Cazajous G, Robert C, Goujon JM, Fakhouri F, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant. 2009;24(2):682–5. https://doi.org/10.1093/ndt/gfn657.

    Article  CAS  PubMed  Google Scholar 

  54. Markowitz GS, Nasr SH, Stokes MB, D’Agati VD. Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5(4):607–15. https://doi.org/10.2215/cjn.07311009.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Xu XJ, Zhao HZ, Tang YM. Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials. Leuk Lymphoma. 2013;54(2):255–60. https://doi.org/10.3109/10428194.2012.715350.

    Article  CAS  PubMed  Google Scholar 

  56. Perazella MA, Shirali AC. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? Kidney Int. 2020;97(1):62–74. https://doi.org/10.1016/j.kint.2019.07.022.

    Article  CAS  PubMed  Google Scholar 

  57. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68. https://doi.org/10.1056/NEJMra1703481.

    Article  CAS  PubMed  Google Scholar 

  58. Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638–47. https://doi.org/10.1016/j.kint.2016.04.008.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Kitchlu A, Fingrut W, Avila-Casado C, Chan CT, Crump M, Hogg D, et al. Nephrotic syndrome with cancer immunotherapies: a report of 2 cases. Am J Kidney Dis. 2017;70(4):581–5. https://doi.org/10.1053/j.ajkd.2017.04.026.

    Article  PubMed  Google Scholar 

  60. Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019;7(1):2. https://doi.org/10.1186/s40425-018-0478-8.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Finkel KW, Cohen EP, Shirali A, Abudayyeh A. Paraprotein-related kidney disease: evaluation and treatment of myeloma cast nephropathy. Clin J Am Soc Nephrol. 2016;11(12):2273–9. https://doi.org/10.2215/cjn.01640216.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Basnayake K, Ying WZ, Wang PX, Sanders PW. Immunoglobulin light chains activate tubular epithelial cells through redox signaling. J Am Soc Nephrol. 2010;21(7):1165–73. https://doi.org/10.1681/asn.2009101089.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica. 2014;99(1):148–54. https://doi.org/10.3324/haematol.2013.087585.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med. 2011;364(24):2365–6. https://doi.org/10.1056/NEJMc1101834.

    Article  CAS  PubMed  Google Scholar 

  65. Bridoux F, Fermand JP. Optimizing treatment strategies in myeloma cast nephropathy: rationale for a randomized prospective trial. Adv Chronic Kidney Dis. 2012;19(5):333–41. https://doi.org/10.1053/j.ackd.2012.07.003.

    Article  PubMed  Google Scholar 

  66. Mirrakhimov AE, Voore P, Khan M, Ali AM. Tumor lysis syndrome: a clinical review. World J Crit Care Med. 2015;4(2):130–8. https://doi.org/10.5492/wjccm.v4.i2.130.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis. 2014;21(1):18–26. https://doi.org/10.1053/j.ackd.2013.07.001.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Sherwood GB, Paschal RD, Adamski J. Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm. Clin Case Rep. 2016;4(4):315–9. https://doi.org/10.1002/ccr3.495.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol. 2012;7(10):1713–21. https://doi.org/10.2215/cjn.02780312.

    Article  CAS  PubMed  Google Scholar 

  70. Hamroun A, Lenain R, Bigna JJ, Speyer E, Bui L, Chamley P, et al. Prevention of cisplatin-induced acute kidney injury: a systematic review and meta-analysis. Drugs. 2019;79(14):1567–82. https://doi.org/10.1007/s40265-019-01182-1.

    Article  PubMed  Google Scholar 

  71. Canet E, Vincent F, Darmon M, Soares M. Acute kidney injury in hematological patients. Curr Opin Crit Care. 2015;21(6):549–58. https://doi.org/10.1097/mcc.0000000000000253.

    Article  PubMed  Google Scholar 

  72. Howard SC, Mccormick J, Pui CH, Buddington RK, Harvey RDJO. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21:1471–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Asati V, Bharti SK, Mahapatra DK. Mutant B-raf kinase inhibitors as anticancer agents. Anticancer Agents Med Chem. 2016;16(12):1558–75. https://doi.org/10.2174/1871520616666160606101848.

    Article  CAS  PubMed  Google Scholar 

  74. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14(7):455–67. https://doi.org/10.1038/nrc3760.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Jhaveri KD, Sakhiya V, Fishbane S. Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib. JAMA Oncol. 2015;1(8):1133–4. https://doi.org/10.1001/jamaoncol.2015.1713.

    Article  PubMed  Google Scholar 

  76. Franzin R, Netti GS, Spadaccino F, Porta C, Gesualdo L, Stallone G, et al. The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand? Front Immunol. 2020;11:574271. https://doi.org/10.3389/fimmu.2020.574271.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol. 2020;31(2):435–46. https://doi.org/10.1681/asn.2019070676.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Shirali AC, Perazella MA, Gettinger S. Association of acute interstitial nephritis with programmed cell Death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis. 2016;68(2):287–91. https://doi.org/10.1053/j.ajkd.2016.02.057.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Shanghai Eighth People’s Hospital Affiliated to Jiangsu University, Shanghai, 200233, People’s Republic of China

    Shuiying Liu, Jinyuan Zhao & Feng Wang

  2. Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, 200233, People’s Republic of China

    Feng Wang

Authors
  1. Shuiying Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jinyuan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Feng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Feng Wang.

Ethics declarations

Conflict of interest

No potential conflict of interest was reported by the author(s).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, S., Zhao, J. & Wang, F. Acute kidney injury in cancer patients. Clin Exp Nephrol 26, 103–112 (2022). https://doi.org/10.1007/s10157-021-02131-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-021-02131-7

Keywords

Search

Navigation